ACE-Inhibitors Associated with Lower Risk for ALS Above Certain Dose Over Time
News Nov 11, 2014
The antihypertensive medications angiotensin-converting enzyme inhibitors (ACEIs) were associated with a 57 percent reduced risk in the chance of developing amyotrophic lateral sclerosis (ALS, also commonly known as Lou Gehrig disease) in patients who were prescribed ACEIs greater than 449.5 cumulative defined daily dose (cDDD) compared with patients who did not use ACEIs, according to a study published online by JAMA Neurology.
ALS is a progressive neurodegenerative disease and most patients die within three to five years after symptoms appear. Studies have suggested ACEIs may decrease the risk for developing neurodegenerative diseases.
Researcher Feng-Cheng Lin, M.D., of the Kaohsiung Medical University Hospital, Taiwan, and fellow co-authors used the total population of Taiwanese citizens to study the association between the use of ACEIs and the risk of developing ALS. The study group included 729 patients diagnosed with ALS between January 2002 and December 2008. They were compared with 14,580 control group individuals. About 15 percent of patients with ALS reported ACEI use between two to five years before their ALS diagnosis, while about 18 percent of the control group without ALS reported ACEI use.
The study results indicate that when compared with patients who did not use ACEIs, the risk reduction was 17 percent (adjusted odds ratio of 0.83) for the group prescribed ACEIs lower than 449.5 cDDD and 57 percent (adjusted odds ratio 0.43) for the group prescribed ACEIs greater than 449.5 cDDD.
"The findings in this total population-based case-control study revealed that long-term exposure to ACEIs was inversely associated with the risk for developing ALS. To our knowledge, the present study is the first to screen the association between ACEIs and ALS risk in a population-based study," note the authors.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Feng-Cheng Lin, Ching-Piao Tsai, Johnny Kuang-Wu Lee, Ming-Tsang Wu, Charles Tzu-Chi Lee. Angiotensin-Converting Enzyme Inhibitors and Amyotrophic Lateral Sclerosis Risk. JAMA Neurology, Published November 10 2014. doi: 10.1001/jamaneurol.2014.3367
Researchers Find a Way to Separate Side Effects of Opioid Drugs Reducing RiskNews
Scientists have discovered a way to separate these two effects -- pain relief and breathing, opening a window of opportunity to make effective pain medications without the risk of respiratory failure.READ MORE
Biological Mechanism of a Leading Cause of Childhood Blindness RevealedNews
Scientists have revealed the pathology of cells and structures stricken by optic nerve hypoplasia, a leading cause of childhood blindness in developed nations.READ MORE
Machine Learning: Helping Determine How a Drug Affects the BrainNews
Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.READ MORE